/PRNewswire/ Standigm, a company using artificial intelligence (AI) technology for drug discovery and development, and Korean non profit research institute.
- Combine Standigm's AI drug discovery platform and Institut Pasteur Korea's research expertise in infectious disease - Accelerate discovery of novel anti-tubercular drug candidates by conducting RIGHT Fund's awarded projects SEOUL, South Korea, Nov. 30, 2021 /PRNewswire/ Standigm Inc. ("Standigm"), the leading workflow artificial intelligence (AI) drug discovery company, today announced the signing of a Memorandum of Understanding.